FS-1502 in patients with HER2 high expression, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: An open-label, multicenter, phase II study.

Hongming Pan, Xianglin Yuan, Yu Zheng, Hui Peng, Hong Qiu, Jufeng Wang, Zhiwei Li, Shegan Gao, Zuoxing Niu, Jianwei Yang, Yifu He, Guowu Wu, Yiyi Yu, Ying Jieer, Yusheng Wang, Zhen Li, Jun Bai, Huilong Liu, Zhuli Wu, Xingli Wang

Journal of Clinical Oncology, 2024

Sir Run Run Shaw Hospital, Zhejiang University, Tongji Hospital, Huazhong University of Science and Technology, Henan Cancer Hospital, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Henan University of Science and Technology, Shandong Tumor Hospital, Shandong First Medical University, Fujian Provincial Cancer Hospital, Anhui Provincial Hospital, Sun Yat-sen University, Meizhou City People's Hospital, Fudan University, Zhongshan Hospital, The First Affiliated Hospital, Sun Yat-sen University, Zhejiang Cancer Hospital, Shanxi Provincial Cancer Hospital, Fosun Pharma (China)

Publisher Website

Abstract

This research paper explore the methodology and findings associated with Journal of Clinical Oncology. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

Citations

View on Google Scholar

FS-1502 in patients with HER2 high expression, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: An open-label, multicenter, phase II study.

Abstract

Journal Details

Join JournalsHub

Welcome Back